Scott Lippman
Overview
Explore the profile of Scott Lippman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez F, Heeke S, et al.
Res Sq
. 2024 May;
PMID: 38798564
Studying lung adenocarcinoma (LUAD) early carcinogenesis is challenging, primarily due to the lack of LUAD precursors specimens. We amassed multi-omics data from 213 LUAD and LUAD precursors to identify molecular...
2.
Sears T, Pagadala M, Castro A, Lee K, Kong J, Tanaka K, et al.
bioRxiv
. 2024 Jan;
PMID: 38293085
Immune Checkpoint Blockade (ICB) has revolutionized cancer treatment, however mechanisms determining patient response remain poorly understood. Here we used machine learning to predict ICB response from germline and somatic biomarkers...
3.
Adashek J, Kato S, Nishizaki D, Miyashita H, De P, Lee S, et al.
Cancer Med
. 2023 May;
12(12):13155-13166.
PMID: 37132280
Background: Lymphocyte activation gene 3 (LAG-3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T-cell activation. Many clinical trials of LAG-3 inhibitors have had...
4.
Jardim D, Millis S, Ross J, Lippman S, Ali S, Kurzrock R
Oncologist
. 2022 Sep;
28(2):e82-e91.
PMID: 36082904
Background: Cyclin pathway gene alterations are frequent in urothelial tumors and may co-exist with other important aberrations, leading to therapeutic opportunities. We characterized the landscape of cyclin gene alterations in...
5.
Shaya J, Cabal A, Nonato T, Torriani F, Califano J, Lippman S, et al.
Cancer Med
. 2021 Oct;
10(24):8763-8767.
PMID: 34708934
Background: Little is known regarding the rate and clinical outcomes of asymptomatic carriers of SARS-CoV-2 among patients with cancer. Detection of asymptomatic carriers is important in this population given the...
6.
Boichard A, Pham T, Yeerna H, Goodman A, Tamayo P, Lippman S, et al.
Oncoimmunology
. 2019 Feb;
8(3):1550341.
PMID: 30723579
Tumor-associated neo-antigens are mutated peptides that allow the immune system to recognize the affected cell as foreign. Cells carrying excessive mutation load often develop mechanisms of tolerance. PD-L1/PD-1 checkpoint immunotherapy...
7.
Ikeda S, Tsigelny I, Skjevik A, Kono Y, Mendler M, Kuo A, et al.
Oncologist
. 2018 Mar;
23(5):586-593.
PMID: 29487225
Background: Because imaging has a high sensitivity to diagnose hepatocellular carcinoma (HCC) and tissue biopsies carry risks such as bleeding, the latter are often not performed in HCC. Blood-derived circulating...
8.
William Jr W, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, et al.
J Am Acad Dermatol
. 2017 Oct;
77(6):1110-1113.e2.
PMID: 28964539
Background: Preclinical data demonstrate a key role for the epidermal growth factor receptor (EGFR) in the carcinogenesis of cutaneous squamous cell carcinomas (CSCCs). There are, however, limited data on the...
9.
Colbert Maresso K, Tsai K, Brown P, Szabo E, Lippman S, Hawk E
CA Cancer J Clin
. 2015 Aug;
65(5):345-83.
PMID: 26284997
The heterogeneity and complexity of advanced cancers strongly support the rationale for an enhanced focus on molecular prevention as a priority strategy to reduce the burden of cancer. Molecular prevention...
10.
Krogan N, Lippman S, Agard D, Ashworth A, Ideker T
Mol Cell
. 2015 May;
58(4):690-8.
PMID: 26000852
Progress in DNA sequencing has revealed the startling complexity of cancer genomes, which typically carry thousands of somatic mutations. However, it remains unclear which are the key driver mutations or...